Document › Details
CureVac AG. (9/10/15). "Press Release: CureVac Establishes U.S. Operations in Cambridge, MA". Tübingen & Cambridge, MA.
|Country||United States (USA)|
|Organisation 2||Novartis Vaccines and Diagnostics Inc.|
|Group||GlaxoSmithKline (GSK) (Group)|
|Product||RNActive® vaccination technology|
|Product 2||RNA-based therapeutic|
|Person||Slobod, Karen (CureVac 201509– Managing Director of new US subsidiary before at Novartis Vaccines)|
|Person 2||Hoerr, Ingmar (CureVac 200601 CEO + co-founder)|
CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.
Headquartered in Tübingen, Germany, where CureVac was founded in 2000 as a spin-off of the University, the expansion into the U.S. extends the company’s footprint into one of the world’s preeminent biotechnology hubs. The US subsidiary will be headed by Karen Slobod, MD, as managing director, formerly Head of the Maternal Immunization Franchise at Novartis Vaccines, and will primarily focus on development activities involving CureVac’s rapidly growing pipeline of mRNA-based prophylactic vaccines, which include programs targeting Rotavirus, RSV, HIV, and influenza virus in collaborations with the Bill & Melinda Gates Foundation, IAVI and Johnson & Johnson. Additionally, the U.S. operations will enable CureVac to more directly engage the U.S. pharmaceutical and investor communities.
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, commented, “Expansion into the U.S. is an important step in CureVac’s corporate and clinical growth as it will enable us to capitalize on the numerous research and business opportunities related to our industry-leading mRNA technology platform. As such our U.S. office will provide an important base for CureVac to extend our U.S. interest, while enhancing our development capabilities, particularly those targeting mRNA-based prophylactic vaccines.”
CureVac’s technology utilizes natural, chemically unmodified mRNA to develop a broad range of therapeutic candidates in cancer immunotherapies and prophylactic vaccines as well as molecular therapy. To date, CureVac has validated its approach in numerous clinical trials, including an ongoing Phase IIb study in prostate cancer. A recent study published in the peer-reviewed journal Molecular Therapy demonstrated that CureVac’s mRNAs are also able to raise relevant protein levels without stimulating an unwanted immune reaction and achieved meaningful biological responses.
CureVac is the leading company in messenger RNA (mRNA) based drugs with more than 15 years of expertise and the most advanced and broadest clinical pipeline in the industry. Until today CureVac received from dievini (Dietmar Hopp) and Bill & Melinda Gates Foundation approx. $225 million in equity investments.
Started in 2008 CureVac’s mRNA products are subject of seven active clinical studies in more than 350 patients and healthy volunteers as of today, including a Phase IIb trial in prostate cancer. CureVac’s mRNA technology is also the foundation for several high-profile partnerships involving multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, and Johnson & Johnson, as well as the Bill & Melinda Gates Foundation and IAVI.
CureVac's proprietary technology platform utilizes natural, chemically unmodified mRNA, which studies have shown elicits greater therapeutic responses than chemically modified mRNA. CureVac’s mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive®), molecular therapies designed to trigger the body's own production of therapeutic proteins (RNArt®), and RNA encoded antibodies (RNAntibody®). In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year.
For more information, please visit www.curevac.com
Tiberend Strategic Advisors, New York
+1 (212) 375-2694
Verena Lauterbach, Manager Communications
CureVac GmbH, Tübingen, Germany
T: +49 (7071) 920 53 756
Record changed: 2017-04-02
More documents for CureVac (Group)
-  CureVac AG. (1/20/17). "Press Release: CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group". Tübingen....
-  CureVac AG. (1/11/17). "Press Release: CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference". San Francisco, CA & Tübingen....
-  CureVac AG. (12/28/16). "Press Release: CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017". Tübingen....
-  CureVac AG. (11/8/16). "Press Release: CureVac Secures an Additional $29.5 Million From Two New Investors". Tübingen....
-  CureVac AG. (10/11/16). "Press Release: CureVac Appoints Pierre Kemula as Chief Financial Officer". Tübingen....
-  CureVac AG. (3/30/16). "Press Release: CureVac Appoints Leading Experts to Its Scientific Advisory Board". Tübingen....
-  CureVac AG. (3/18/16). "Press Release: CureVac Strengthens Supervisory Board to Support Global Growth Opportunities and mRNA Product Expansion". Tübingen....
-  CureVac AG. (1/6/16). "Press Release: CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference". Tübingen....
-  Rittershaus Rechtsanwälte. (11/3/15). "Press Release: Rittershaus Advises CureVac on EUR 100 Million Financing Round". Mannheim....
-  CureVac AG. (11/2/15). "Press Release: CureVac Raises $110 Million in a Private Placement". Darmstadt....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)